Sanofi

FADEL Announces Strong FY23 Results With YOY Revenues Up 10%

Retrieved on: 
화요일, 4월 30, 2024
Account, Licensee, Investment, PepsiCo, Annual report, FADEL, Philip Morris, Kimberly-Clark, Sanofi, Growth

NEW YORK, April 30, 2024 /PRNewswire-PRWeb/ -- FADEL®, innovator of brand compliance and rights and royalty management software, has today announced its audited full-year results for the year ended December 31, 2023, with revenue up 10% on FY22 to $14.5 million and recurring revenue up 31% on FY22 to $11.4 million.

Key Points: 
  • I am extremely proud to report that we have delivered on that in our first financial year as a listed company.
  • FADEL has made great strides during the year.
  • In addition to its successful IPO, the Company has achieved exceptional client wins of powerhouse net-new clients including PepsiCo, Kimberly-Clark, Sanofi, and Philip Morris.
  • FADEL has expanded its product portfolio – under Brand Vision and IPM Suite – to meet the needs of existing clients and strategically penetrate new territories and markets.

Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024

Retrieved on: 
목요일, 4월 25, 2024
Conditional sentence, Sarilumab, Ulcerative colitis, AbbVie, Research, Roche, Novartis, Patient, Psoriasis, Secukinumab, Morphic, Human Genome Sciences, Drug development, Clinical trial, Therapy, Sanofi, Organization, UC, Pharmaceutical industry

WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter 2024.

Key Points: 
  • -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027-
    WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the first quarter 2024.
  • “Morphic continues to execute our strategy with the EMERALD-2 phase 2b study in ulcerative colitis (UC) recruiting on target, and we are excited to begin enrollment in the GARNET phase 2 study in patients with moderate to severe Crohn’s disease (CD),” commented Praveen Tipirneni, CEO of Morphic Therapeutic.
  • “We look forward to continued progress both with MORF-057 and our earlier-stage pipeline, including our program in pulmonary hypertensive diseases.
  • The increase was primarily attributable to increased non-cash stock-based compensation expenses
    Based on its current operating plan, Morphic believes its existing cash, cash equivalents and marketable securities as of March 31, 2024, will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2027.

Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts

Retrieved on: 
목요일, 4월 25, 2024
Genetics, CMO, Doctor of Philosophy, Boston, Development, Novartis, Pfizer, Operating partner, Functional genomics, CSO, Genome, Associate, Drug discovery, SAB, AbbVie, Baxalta, EVP, GSK plc, Bristol Myers Squibb, GSK, Baylor College of Medicine, University, Harvard Medical School, Therapy, Biotechnology, Inflammation, Hospital, NIH, Michigan State University, Respiratory Medicine, Imperial College London, IPO, Rockefeller University, Spatial, MPH, Genomics, Atlas Venture, Merck Serono, Genentech, University of Birmingham, Senior, Society, Acquisition, Discovery, Sanofi, Baylor University

New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.

Key Points: 
  • New Non-Executive Director of the Board, John Davis MD, MPH, MS, brings extensive and varied experience as a physician-scientist, drug developer and biotechnology executive.
  • The SAB is chaired by Prof. Jim Hughes, Scientific Founder and Non-Executive Director of Nucleome Therapeutics.
  • Dr Russell Greig, Non-Executive Chair of the Nucleome’s Board, said: “We are delighted to have appointed such esteemed experts to the Nucleome team.
  • Steve’s multifaceted background, spanning academia, industry and leadership roles, positions him as a key contributor to Nucleome’s Scientific Advisory Board.

Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia

Retrieved on: 
화요일, 4월 23, 2024
FDA, DSM-IV codes, Prurigo nodularis, Fast track (FDA), Safety, Risk, ITP, Food, Thrombocytopenia, Orphan, Research and development, Development, Patient, Fatigue, Intracranial hemorrhage, LUNA, Asthma, Sanofi, Hematology, BTK, IgG4-related disease

Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).

Key Points: 
  • Positive results from the LUNA 3 phase 3 study demonstrated that rilzabrutinib 400 mg twice daily orally achieved the primary endpoint of durable platelet response in adult patients with persistent or chronic immune thrombocytopenia (ITP).
  • The safety profile of rilzabrutinib was consistent with that reported in previous studies.
  • LUNA 3 study met its primary endpoint demonstrating a significantly higher proportion of patients receiving rilzabrutinib achieved the primary endpoint of durable platelet response versus placebo.
  • This clinically and statistically significant result was achieved in a population of patients with primary ITP that had been refractory to prior therapy.

IGM Biosciences Announces Refocusing of Sanofi Collaboration

Retrieved on: 
수요일, 4월 17, 2024
Immunoglobulin M, IGM, Antibody, Sanofi

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.

Key Points: 
  • MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets.
  • IGM will retain global rights to its proprietary technology related to the oncology targets nominated by Sanofi under the collaboration.
  • “We are very pleased with our collaboration with Sanofi and with the preclinical data that we have generated in both the immunology/inflammation and the oncology portions of the collaboration,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • IGM will be eligible to receive up to $1,065 million in aggregate development, regulatory and commercial milestones per target as well as tiered high single-digit to low-teen royalties on global net sales.

E2open Announces Connect Europe 2024 Client Award Winners

Retrieved on: 
목요일, 5월 2, 2024
Supply Chain Management, Data Management, Retail, Technology, Logistics, Transport, Software, Supply, RTTV, Partnership, JLR, Software as a service, RS Group, Sanofi, Connect, Video game

E2open Parent Holdings, Inc. (NYSE: ETWO), the connected supply chain SaaS platform with the largest multi-enterprise network, announced the winners of its Connect Europe 2024 Client Awards, celebrated at its annual international customer conference in Amsterdam last week.

Key Points: 
  • E2open Parent Holdings, Inc. (NYSE: ETWO), the connected supply chain SaaS platform with the largest multi-enterprise network, announced the winners of its Connect Europe 2024 Client Awards, celebrated at its annual international customer conference in Amsterdam last week.
  • A longstanding client, JLR uses multiple e2open solutions as part of a strategic directive to reimagine supply chain operations by harnessing technology innovation to drive efficiency and connectivity.
  • Sanofi received the Supply Chain Innovator Award, honoring an industry trailblazer and visionary shaping the future of supply chain management.
  • For exceptional achievement in real-time supply chain visibility and transparency, the Supply Chain Visibility Award was presented to RS Group.

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Retrieved on: 
수요일, 4월 10, 2024
Mantle cell lymphoma, MCL, FDA, Cancer, Inflammation, DLBCL, Paclitaxel, Gilead Sciences, Research, PCNSL, Partnership, B-cell lymphoma, Trial of the century, STAT6, IND, CNS, Lymphoma, Patient, Rheumatoid arthritis, NHL, Chronic lymphocytic leukemia, Central nervous system, AACR, Neoplasm, Clinical trial, Annual general meeting, Therapy, Sanofi, Lymphoid leukemia, Non-Hodgkin lymphoma, Calendar, SAN, BTK, Pharmaceutical industry

SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.

Key Points: 
  • SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.
  • Nurix and Sanofi extended their ongoing research program for STAT6 (signal transducer and activator of transcription 6).
  • Nurix retains its option to co-develop and co-promote future products in the United States under programs for which Nurix has exercised its option.
  • Nurix presented new clinical data for NX-5948 at the American Association for Cancer Research (AACR) 2024 Annual Meeting.

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Retrieved on: 
수요일, 4월 24, 2024
Health, Pharmaceutical, Technology, Artificial Intelligence, Oncology, Brain, Fox Chase Cancer Center, AIDS, Lung cancer, AI, Pancreatic cancer, Ambulatory care, Hematology, Machine learning, MD, Doctor of Philosophy, National Cancer Institute, Research, Ohio State University, Artificial intelligence, Disease, Science, Patient, NCI, Physician, Neoplasm, Central nervous system, Diagnosis, Drug development, Associate, Sanofi, Kishor, Medical director, AstraZeneca, Pharmaceutical industry

The series begins today, Wednesday, April 24, 2024, and is planned to be held on the last Wednesday of each month.

Key Points: 
  • The series begins today, Wednesday, April 24, 2024, and is planned to be held on the last Wednesday of each month.
  • Each webinar will feature a presentation from a Lantern collaborator, advisor, or researchers followed by a live Q&A.
  • These sessions provide a deep dive into the company’s research, collaborations, clinical trials and expected goals for the drug or AI development initiatives.
  • Igor Astsaturov, MD is a leading expert in pancreatic cancer collaborating with Lantern Pharma on the LP-184 clinical trial.

COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials

Retrieved on: 
수요일, 4월 17, 2024
Health Technology, Health, Oncology, Disease, Cancer, Multiple myeloma, Partnership, Patient, Sanofi, Trial of the century, RWD, Artificial intelligence, Pharmacy, Medical imaging

COTA , a leader in real-world data (RWD) and analytics for oncology, today announced a strategic collaboration with Sanofi to use RWD and artificial intelligence (AI) to increase the speed of oncology trials, including for multiple myeloma.

Key Points: 
  • COTA , a leader in real-world data (RWD) and analytics for oncology, today announced a strategic collaboration with Sanofi to use RWD and artificial intelligence (AI) to increase the speed of oncology trials, including for multiple myeloma.
  • The partnership will be valuable to understand clinical outcomes that may ultimately be beneficial for patients living with cancer.
  • COTA’s RWD offers critical insights into effective cancer treatment pathways and will provide valuable context on key patient populations.
  • “Our collaboration with Sanofi has the potential to enable more patients and their families to benefit from breakthrough treatments in an expedited time frame,” said Dr. C.K.

BioNJ Announces Lineup for BioPartnering Conference

Retrieved on: 
목요일, 4월 25, 2024
Corporation, Ecosystem, Johnson & Johnson, Conference, Merck & Co., J. P. Morgan, Partner, Ferring Pharmaceuticals, Liberty Science Center, Osteonecrosis of the jaw, Sanofi, Teva Pharmaceuticals, Economic development, Health, Pharmaceutical industry

TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City.

Key Points: 
  • TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City.
  • The action-packed schedule is designed to create meaningful opportunities, grow the ecosystem and bolster medical innovation.
  • "The BioPartnering Conference is the ideal chance to discover innovative companies for investment portfolios," BioNJ President and CEO Debbie Hart noted.
  • "We have more than 90 companies from the life sciences, biotech, healthcare and digital health sectors presenting new innovations and technologies.